CoChat

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

Open access
Vermeeren, Annemiek, Jongen, Stefan, Murphy, Patricia, Moline, Margaret, Filippov, Gleb, Pinner, Kate, Perdomo, Carlos, Landry, Ishani, Majid, Oneeb, Van Oers, Anita C M, Van Leeuwen, Cees J, Ramaekers, Johannes G, Vuurman, Eric F P M · 2019 · Sleep
Cited by 228

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Study Objectives: To assess potential effects of lemborexant on next-morning driving performance in adult and elderly healthy volunteers. Methods: Randomized, double-blind, double-dummy, placebo and active-controlled, four period incomplete crossover study in 48 healthy volunteers (22 females), 23–78 years old. Participants were treated at bedtime for eight consecutive nights with two of three dose levels of lemborexant (2.5, 5, or 10 mg), zopiclone 7.5 mg (on the first and last night with placebo on intervening nights), or placebo. Driving performance was assessed in the morning on days 2 and 9 using a standardized highway driving test in normal traffic, measuring standard deviation of lateral position (SDLP). Drug–placebo differences in SDLP >2.4 cm were considered to reflect clinically meaningful driving impairment. Results: Mean drug–placebo differences in SDLP following lemborexant 2.5, 5, and 10 mg on days 2 and 9 were 0.74 cm or less. The upper bound of the 95% confidence intervals (CIs) for lemborexant treatment groups were all below 2.4 cm and the 95% CIs included zero, indicating that the effects were neither clinically meaningful nor statistically significant. Symmetry analysis further supported the lack of clinically meaningful impairment with lemborexant. Conclusions: When assessed starting ~9 h after lemborexant administration at bedtime the previous night, there was no statistically significant or clinically meaningful effect on driving performance in healthy adults and elderly, as assessed by either mean differences in SDLP relative to placebo or symmetry analysis. In this study, lemborexant at doses up to 10 mg was well-tolerated. Clinical Trial Registration: clinicaltrials.gov, NCT02583451. https://clinicaltrials.gov/ct2/show/NCT02583451.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/sleep/zsy260

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Functional Neuroimaging Evidence for Hyperarousal in Insomnia

    Nofzinger, E. A., Buysse, D. J., Germain, A., Price, J. C., Miewald, J. M., & Kupfer, D. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2126 · Cited by 752 · cited 1×

    “Data such as these support the hypothesis that insomnia can be due to an inability of the brain to switch off wake-promoting systems such as the orexin system, as well as an inability to switch on sleep promoting circuits [10].”
    Background

Show all 1 references

Cited by

See all 228

Metadata

Authors
Vermeeren, A., Jongen, S., Murphy, P., Moline, M., Filippov, G., Pinner, K., Perdomo, C., Landry, I., Majid, O., Van Oers, A. C. M., Van Leeuwen, C. J., Ramaekers, J. G., & Vuurman, E. F. P. M.
Venue
Sleep
Published
2018-12-31
Volume
42
Issue
4
ISSN
  • 0161-8105 (ISSN-L)
  • 1550-9109
OpenAlex
W2907565595
Cited by
228
References
1
FWCI
55.84
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. https://app.cochat.ai/papers/10.1093/sleep/zsy260
The paper
Vermeeren, A., Jongen, S., Murphy, P., Moline, M., Filippov, G., Pinner, K., Perdomo, C., Landry, I., Majid, O., Van Oers, A. C. M., Van Leeuwen, C. J., Ramaekers, J. G., & Vuurman, E. F. P. M. (2019). On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep. https://doi.org/10.1093/sleep/zsy260

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.